Sophia S. Li, MPH

Genentech, Inc.

Poster(s):

• (137) Lower total cost of care of first-line fixed-duration venetoclax + obinutuzumab vs treat-to-progression Bruton’s tyrosine kinase inhibitor regimens in patients with chronic lymphocytic leukemia in the United States: a population-based model
  Wednesday, October 29, 2025